8-K: Calidi Biotherapeutics Provides Preliminary Financial Update for Year-End 2023

Calidi Biotherapeutics released preliminary financial estimates for the quarter and year ended December 31, 2023, including cash, cash used in operations, and indebtedness.

Summary

• Calidi Biotherapeutics has provided a preliminary financial update for the quarter and year ended December 31, 2023.
• The company estimates it had approximately $1.9 million in cash and cash equivalents as of December 31, 2023.
• Cash used in operations is estimated to be $27.4 million for the same period.
• The company also estimates $3.4 million in aggregate principal amount of indebtedness as of December 31, 2023.
• These figures are preliminary and have not been audited, and are subject to change upon completion of the financial close process.
• The company's independent accounting firm has not reviewed these preliminary results and does not express any opinion or assurance about them.

Sentiment

Score: 3

Explanation: The preliminary financial results indicate a weak cash position and high cash burn, which is concerning for investors. The lack of an audit and the forward-looking statements add to the uncertainty.

Negatives

• The company used $27.4 million in cash for operations during the year ended December 31, 2023.
• The preliminary nature of the financial results and the lack of an audit introduce uncertainty.

Risks

• The preliminary financial results are subject to change upon completion of the financial close process.
• The company's independent accounting firm has not reviewed these preliminary results.
• Actual results may vary materially from these preliminary estimates due to various risks and uncertainties.

Future Outlook

The company acknowledges that actual results may differ materially from these preliminary estimates and that they are not obligated to update these forward-looking statements.

Management Comments

• The company's CFO, Andrew Jackson, signed the report on behalf of Calidi Biotherapeutics.

Industry Context

This announcement is typical for a company providing a financial update before the full release of audited results, which is common in the biotechnology sector.

Comparison to Industry Standards

• It is difficult to compare these preliminary results to industry standards without knowing the specific stage of development and financial position of comparable companies.
• Companies like Iovance Biotherapeutics and Adaptimmune Therapeutics, which are also in the immuno-oncology space, would be relevant comparables, but their financial situations and cash burn rates vary significantly based on their clinical trial progress and commercialization efforts.
• A more detailed analysis would require a full set of audited financial statements and a deeper understanding of Calidi's specific pipeline and operational costs.

Stakeholder Impact

• Shareholders may be concerned about the company's low cash position and high cash burn.
• Employees may be concerned about the company's financial stability.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will complete its quarter-end financial close process for the quarter ended December 31, 2023.
• The company will likely release audited financial statements in the future.

Key Dates

Keywords

financial results, cash, cash equivalents, indebtedness, preliminary, operations, biotherapeutics